 |
USA Edition | Today Is Wednesday, June 19, 2013 |
|---|
Socratic Warning
Newsroom Magazine
May Challenge
Or Demand
Critical Thinking
|
|---|
|
|
The intellectual roots of critical thinking date back to the Greek philosophers.
Socrates discovered, by means of probing questions, that in the exchange of competing ideas, people sometimes make confident claims based on unreliable assumptions or failed logic.
Such arguments, he discovered, were either erroneous in fact, absent sufficient foundation, or failing in logic. Instead, most arguments were based on confused meanings, inadequate evidence, or contradictory beliefs.
Socrates' contributions to critical thinking were many -- for he established new ways to think about contentious issues in terms of the quality of assumptions, facts and logic.
Thus Socrates demonstrated that persons may have passion, or power or high position but yet be deeply confused and irrational.
Good journalism, like compelling debate, is based on a clear understanding of facts and the logical construction of one's argument. And that is what the Socratic Method and The Sophist Tradition is all about.
Evidentiary Approach
The Socratic Method is the preferred way to examine issues.In the Socratic mode of questioning, postulations, ideas or arguments are examined for their clarity and logical consistency by systematic analysis of facts, assumptions and logical methodology to support a conclusion.
Socratic analysis is accomplished by means of a series of probing questions that systematically examine the quality of an argument or conclusion.
Understanding the quality of information, argument or one's conclusions, is fundamental to critical thinking -- and the goal of critical editing.
Historical Foundation
Socrates’ practice was followed by the critical thinking of Plato (who recorded Socrates’ thought), Aristotle, and the Greek skeptics, all of whom emphasized that things are often very different from what they appear to be.Only the trained mind is prepared to see through the way things look to us on the surface (delusive appearances) to the way they really are beneath the surface (the deeper realities of life.)
From this ancient Greek tradition emerged the need, for anyone who aspired to understand the deeper realities, to think systematically, to trace implications broadly and deeply; for only thinking that is comprehensive, well-reasoned, and responsive to objections can take us beyond the surface.
Means Of Analysis
The common denominators of Critical Thinking requires, for example, the systematic monitoring of thought; that thinking, to be critical, must not be accepted at face value, but must be analyzed and assessed for its clarity, accuracy, relevance, depth, breadth, and logical validity. All reasoning occurs within points of view and frames of reference.All reasoning proceeds from some goals, objectives, and has an informational base. All data, when used in reasoning, must be interpreted. That interpretation involves concepts, that concepts entail assumptions, and that all basic inferences in thought have implications, and each of these dimensions of thinking need to be monitored where problems of thinking can occur.
Questioning Chain
The result of the collective contribution of the history of critical thought is that the basic questions of Socrates can now be much more powerfully and focally framed.In every domain of human thought, and within every use of reasoning within any domain, it is now possible to question:
• ends and objectives
• the status and wording of questions
• the sources of information and fact
• the method and quality of information collection
• the mode of judgment and reasoning used
• the concepts that make that reasoning possible
• the assumptions that underlie concepts in use
• the implications that follow from their use
• the point of view or frame of reference within which reasoning takes place
Jeffrey Slee
Logician
| Rapid Security Deterioration In North Darfur Region | Browse All Content | Justice Settles E-Book Pricing Case Against Macmillan, To Continue Litigation Against Apple | |||
|---|---|---|---|---|---|
| Previous In Section | Browse National Institutes Of Health Section |
Next In Section |
Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the drug bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an interim analysis of a large, randomized clinical trial.
Washington
Bevacizumab Significantly Improves Survival For Patients With Recurrent And Metastatic Cervical Cancer
February 8, 2013
Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the drug bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an interim analysis of a large, randomized clinical trial.
The clinical trial, known as GOG240, was sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and conducted by a network of researchers led by the Gynecological Oncology Group (GOG). Genentech, Inc., South San Francisco, Calif., the drug manufacturer, provided support for the trial under the Cooperative Research and Development Agreement (CRADA) with NCI for the clinical development of bevacizumab.
The data safety monitoring committee overseeing the trial recommended that the results of a recent interim analysis be made public because the study had met its primary endpoint of demonstrating improved overall survival in patients who received bevacizumab, which also means that it delayed the chance of dying from the disease.
Patients who received bevacizumab got a dose of 15 milligrams per kilogram (mg/kg) of body weight administered in the vein with their chemotherapy treatment and continued with this dose one day every three weeks until disease progression or unacceptable toxicity occurred. Those patients lived a median 3.7 months longer than those who did not receive bevacizumab. Patients treated with chemotherapy alone had a median survival of 13.3 months while those who received chemotherapy and bevacizumab had a median survival of 17 months. This survival difference was highly statistically significant. However, patients receiving bevacizumab experienced more side effects than those who did not. These side effects were consistent with side effects previously known to be associated with bevacizumab.
“The findings in this clinical trial are important because they are likely to change clinical practice and provide an opportunity to improve outcome in patients with recurrent cervical cancer who have previously had very limited treatment options,” said GOG study chair Krishnansu S. Tewari, M.D.
A total of 452 patients in the United States and Spain with metastatic, recurrent, or persistent cervical cancer not curable with standard treatment were enrolled between 2009 and 2012. The trial was designed to answer two questions: Whether topotecan in combination with paclitaxel was superior to cisplatin and paclitaxel in combination, and whether the addition of bevacizumab to either regimen improved overall survival.
Patients were randomly assigned to one of four treatment groups; two of the treatment groups received bevacizumab. In an analysis conducted in 2012, it was determined that topotecan plus paclitaxel was not superior to the standard therapy of cisplatin plus paclitaxel and investigators and patients were notified of the finding at that time.
The purpose of bevacizumab is to block the blood supply that feeds the tumor. The drug originally was approved for certain types of metastatic cancer in combination with chemotherapy and is designed to bind to and inhibit vascular endothelial growth factor (VEGF). VEGF is a protein that plays a critical role in tumor blood vessel growth.
“This is welcome news as progress has been very difficult against this cancer, and GOG physicians and patients who participated have made an important contribution,” said Jeff Abrams, M.D., clinical director of NCI’s Division of Cancer Treatment and Diagnosis.
It is estimated that over 12,000 women will be diagnosed with cervical cancer in the United States in 2013 and over 4,000 women will die of the disease.
Full data has been submitted to the American Society of Clinical Oncology 2013 Annual Meeting. The trial is GOG240, Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab for Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer, clinical trial registry number NCT00803062.
